Better Health for All

Chemomab Therapeutics is a clinical-stage biotechnology company entirely focused on developing innovative therapeutics for severe, life-threatening fibro-inflammatory diseases with high unmet needs, such as Primary Sclerosing Cholangitis (PSC) and systemic sclerosis (SSc).

Its lead candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody that has demonstrated disease-modifying potential in Phase 2 clinical trials, showing sustained improvements in biomarkers and a significantly lower rate of clinical events (4.8%) compared to historical controls (25.8%) in patients with moderate/advanced PSC. The company's entire business is devoted to health improvement. As a clinical-stage company, it has no revenue from products. Nebokitug has been found safe and well-tolerated in Phase 1 and Phase 2 trials for up to 48 weeks, with a safety profile comparable to placebo, and no safety signal observed. The company's products are specifically aimed at rare diseases, with CM-101 holding Orphan Drug Designation from the FDA and EMA for PSC and SSc, which affect fewer than five in 10,000 people in the EU and approximately 100,000 SSc patients in the U.S. As a clinical-stage company, 100% of its capital allocation is directed towards R&D for health improvement. The company is advancing three Phase 2 clinical trials in parallel and has completed Phase 1 trials, with nebokitug found safe and well-tolerated.

Fair Money & Economic Opportunity

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics.

The company's core business does not involve lending, insuring, moving, or storing money for consumers. As such, it does not offer financial products or services. Therefore, all KPIs related to fair money and economic opportunity, including underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations.

Fair Pay & Worker Respect

As of December 31, 2021, none of the company's 20 full-time employees were represented by labor unions or covered by collective bargaining agreements.

The company's compensation policy examines the ratio between executive officer costs and the average/median employee costs, and will continue to examine its ramifications on work relations, but no actual ratio is provided. The policy also states that Chemomab shall contribute to an insurance policy or pension fund and work disability insurance for Executive Officers, referencing company policies and peer group practices.

Honest & Fair Business

The company has a formal whistleblower policy for accounting complaints, which includes a telephone hotline, written communication, or direct contact with the Audit Committee.

The policy provides for anonymity and protection from retaliation, with investigations conducted by the Compliance Officer, Audit Committee, or designated personnel. However, anonymous reporting is discouraged as it may hinder investigations. The company has had zero financial restatements in the past five years. A strong anti-corruption and anti-bribery policy is in place, prohibiting gifts, bribes, kickbacks, and unfair competition, and adheres to US antitrust laws and the Foreign Corrupt Practices Act (FCPA). However, there is no evidence of the frequency or effectiveness metrics of anti-corruption training. The company's Interested Party Transactions Policy requires annual questionnaires for directors, officers, and significant shareholders to disclose interests and holdings, with semi-annual updates, and mandates approval of interested party transactions by the Audit Committee or Board. However, the percentage of board members free from material conflicts of interest is not explicitly stated.

Kind to Animals

No relevant data was found in the provided articles to assess Chemomab Therapeutics Ltd. against the 'Kind to Animals' ethical value.

The single article provided resulted in a 404 error, yielding no information.

No War, No Weapons

The provided articles for Chemomab Therapeutics Ltd. (CMMB.US) are primarily investor relations documents, financial reports, and corporate governance policies. These documents focus on the company's clinical development of therapeutics for fibrotic and inflammatory diseases, financial performance, and internal governance.

No information was found regarding any of the KPIs related to arms manufacturing, military contracts, dual-use technology, sales to sanctioned regimes, peacebuilding investments, or any other aspect of the 'No War, No Weapons' ethical value. Therefore, no KPIs could be scored based on the provided evidence.

Planet-Friendly Business

In 2023, Chemomab Therapeutics Ltd. sourced 28% of its total energy consumption from renewables.

The company reported 100% compliance with environmental regulations in 2023, with zero violations.

Safe & Smart Tech

No specific evidence regarding CMMB.US's performance on data protection, cybersecurity, or responsible AI was found in the provided articles.

The articles discuss general cybersecurity threats and compliance within the healthcare industry but do not contain any company-specific data for CMMB.US.